Halozyme Therapeutics, Inc.HALONASDAQ

Revenue (LTM)

$1.4B

+37.6% YoY

Net Income (LTM)

$317M

-28.6% YoY

Free Cash Flow

$645M

Revenue CAGR (5Y)

+33.2%

—Marginsstable

FCF$0.6B

Profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	443	660↑48.9%	829↑25.6%	1,015↑22.4%	1,397↑37.6%
Gross Profit	362	521↑43.9%	637↑22.3%	856↑34.4%	1,091↑27.5%
Operating Income	276	268↓3.0%	338↑26.2%	551↑63.4%	816↑48.0%
Net Income	403	202↓49.8%	282↑39.3%	444↑57.7%	317↓28.6%
EBITDA	259	316↑21.8%	452↑43.2%	657↑45.3%	904↑37.7%
EPS Diluted	2.74	1.44↓47.4%	2.10↑45.8%	3.43↑63.3%	2.56↓25.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	119	234↑97.3%	118↓49.5%	116↓2.1%	134↑15.5%
Total Current Assets	926	739↓20.2%	746↑1.0%	1,085↑45.4%	825↓24.0%
Total Assets	1,104	1,842↑66.7%	1,733↓5.9%	2,063↑19.1%	2,525↑22.4%
Total Current Liabilities	117	131↑11.6%	112↓14.0%	139↑23.7%	177↑27.3%
Total Liabilities	907	1,672↑84.2%	1,649↓1.3%	1,700↑3.0%	2,477↑45.7%
Total Equity	197	170↓13.8%	84↓50.6%	364↑334.1%	49↓86.6%
Total Debt	877	1,506↑71.8%	1,499↓0.5%	1,506↑0.4%	0
Net Debt	758	1,272↑67.8%	1,381↑8.6%	1,390↑0.7%	-134↓109.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	299	240↓19.8%	389↑61.8%	479↑23.3%	652↑36.0%
Capital Expenditure	-1	-5↓230.1%	-15↓218.0%	-11↑30.1%	-7↑34.8%
Free Cash Flow	298	235↓21.0%	373↑58.6%	468↑25.5%	645↑37.6%
Stock-Based Comp	21	24↑17.2%	37↑50.1%	43↑18.5%	52↑18.9%
Net Change in Cash	-29	115↑498.4%	-116↓200.7%	-3↑97.8%	21↑916.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance